JP2007527430A - 肺疾患の感染性を低下させる処方物 - Google Patents

肺疾患の感染性を低下させる処方物 Download PDF

Info

Publication number
JP2007527430A
JP2007527430A JP2007501976A JP2007501976A JP2007527430A JP 2007527430 A JP2007527430 A JP 2007527430A JP 2007501976 A JP2007501976 A JP 2007501976A JP 2007501976 A JP2007501976 A JP 2007501976A JP 2007527430 A JP2007527430 A JP 2007527430A
Authority
JP
Japan
Prior art keywords
formulation
group
particles
aerosol
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007501976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007527430A5 (enExample
Inventor
デイビッド エー． エドワーズ，
ジョナサン シー． マン，
ジェフリー ピー． カツトラ，
ロバート ダブリュー． クラーク，
Original Assignee
プルマトリックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プルマトリックス インコーポレイテッド filed Critical プルマトリックス インコーポレイテッド
Publication of JP2007527430A publication Critical patent/JP2007527430A/ja
Publication of JP2007527430A5 publication Critical patent/JP2007527430A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007501976A 2004-03-05 2005-03-03 肺疾患の感染性を低下させる処方物 Pending JP2007527430A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US55060104P 2004-03-05 2004-03-05
US56047004P 2004-04-07 2004-04-07
US56418904P 2004-04-21 2004-04-21
US57263104P 2004-05-19 2004-05-19
US57942504P 2004-06-14 2004-06-14
US10/990,996 US20050207983A1 (en) 2004-03-05 2004-11-17 Formulations decreasing particle exhalation
PCT/US2005/006903 WO2005084638A2 (en) 2004-03-05 2005-03-03 Formulations decreasing infectivity of pulmonary diseases

Publications (2)

Publication Number Publication Date
JP2007527430A true JP2007527430A (ja) 2007-09-27
JP2007527430A5 JP2007527430A5 (enExample) 2007-12-20

Family

ID=34923561

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007501976A Pending JP2007527430A (ja) 2004-03-05 2005-03-03 肺疾患の感染性を低下させる処方物

Country Status (6)

Country Link
US (4) US20050207983A1 (enExample)
EP (1) EP1732606A2 (enExample)
JP (1) JP2007527430A (enExample)
AU (2) AU2005219431B2 (enExample)
CA (1) CA2558426C (enExample)
WO (1) WO2005084638A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540959A (ja) * 2007-10-02 2010-12-24 オリン，アナ−キャリン 呼気粒子の捕集及び測定
JP2012522011A (ja) * 2009-03-26 2012-09-20 パルマトリックス，インコーポレイテッド 気道感染症を治療するための医薬製剤および方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2483917C (en) * 2002-05-02 2013-07-30 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
JP2008540680A (ja) 2005-05-18 2008-11-20 プルマトリックス インコーポレイテッド 粘膜内壁の生物物理学的な性質を変化させる製剤
EP1834651A1 (en) * 2006-03-15 2007-09-19 Universiteit Gent Compositions and methods for veterinary vaccination
WO2008055208A1 (en) * 2006-11-01 2008-05-08 New Jersey Institute Of Technology Aerogel-based filtration of gas phase systems
US20080260863A1 (en) * 2007-04-20 2008-10-23 Pre Holding, Inc. Compositions for mucociliary clearance and methods for administering same
CA2754684A1 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
EP2410981B2 (en) 2009-03-26 2020-02-26 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2010111640A2 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Anti-influenza formulations and methods
WO2012012498A2 (en) * 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
CA2812417C (en) 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
CN107096014B (zh) 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
KR101211672B1 (ko) 2010-12-10 2012-12-12 한국철도기술연구원 재채기 모사장치 및 모사방법
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
MA41124A (fr) * 2014-12-05 2017-10-10 Sun Pharmaceutical Ind Ltd Compositions en suspension à libération prolongée à rétention gastrique
US12337064B2 (en) 2018-09-05 2025-06-24 Sensory Cloud, Inc. Formulations and compositions for ortho- and/or retro-nasal delivery and associated systems, methods and articles
US20220000767A1 (en) * 2020-07-06 2022-01-06 Sensory Cloud, Inc. Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi
US20220051592A1 (en) * 2020-08-17 2022-02-17 Massachusetts Institute Of Technology Respiratory system simulator systems and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0367723A2 (en) * 1988-11-04 1990-05-09 Ciba-Geigy Ag Method for producing a sterile preservative-free aerosol solution
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3229179C2 (de) 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Lungensurfactant
US4826844A (en) * 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
US5466680A (en) 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
JP3961029B2 (ja) 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
US5709202A (en) * 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
AUPM411494A0 (en) * 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5633003A (en) 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
US5633033A (en) * 1994-04-18 1997-05-27 Matsushita Electric Industrial Co., Ltd. Method for manufacturing chalcopyrite film
US5863563A (en) 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
USRE37053E1 (en) * 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US5883084A (en) 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
FR2780285B1 (fr) 1998-06-29 2001-10-05 Goemar Lab Sa Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
WO2002009574A2 (en) * 2000-08-01 2002-02-07 Shofner Engineering Associates, Inc. Generation, delivery, measurement and control of aerosol boli for diagnostics and treatment of the respiratory tract
AU2002245181B2 (en) * 2000-12-21 2006-06-29 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US6660249B2 (en) * 2000-12-27 2003-12-09 Salus Pharma, Inc. Inhalable dry powder aztreonam for treatment and prevention of pulmonary bacterial infections
US20030138403A1 (en) * 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
CA2483917C (en) * 2002-05-02 2013-07-30 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
EP1503744A1 (en) * 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US20070275091A1 (en) 2004-03-30 2007-11-29 Malcolm King Compositions And Methods For Improved Mucus Function
US8627821B2 (en) 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
WO2006102438A2 (en) 2005-03-23 2006-09-28 Ihc Intellectual Asset Management, Llc Methods and compositions for irrigation of mucosal tissues
JP2008540680A (ja) 2005-05-18 2008-11-20 プルマトリックス インコーポレイテッド 粘膜内壁の生物物理学的な性質を変化させる製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0367723A2 (en) * 1988-11-04 1990-05-09 Ciba-Geigy Ag Method for producing a sterile preservative-free aerosol solution
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US6083922A (en) * 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540959A (ja) * 2007-10-02 2010-12-24 オリン，アナ−キャリン 呼気粒子の捕集及び測定
JP2012522011A (ja) * 2009-03-26 2012-09-20 パルマトリックス，インコーポレイテッド 気道感染症を治療するための医薬製剤および方法

Also Published As

Publication number Publication date
CA2558426A1 (en) 2005-09-15
AU2005219431B2 (en) 2009-07-16
US8591866B2 (en) 2013-11-26
EP1732606A2 (en) 2006-12-20
AU2009225363A1 (en) 2009-11-05
US20130078282A1 (en) 2013-03-28
AU2005219431A8 (en) 2009-07-02
US20070270502A1 (en) 2007-11-22
WO2005084638A2 (en) 2005-09-15
AU2009225363B2 (en) 2012-02-23
CA2558426C (en) 2011-05-03
US20050207983A1 (en) 2005-09-22
AU2005219431A1 (en) 2005-09-15
US8187637B2 (en) 2012-05-29
WO2005084638A3 (en) 2006-06-15
US20150079173A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
US8591866B2 (en) Formulations decreasing particle exhalation
US8858917B2 (en) Methods for limiting spread of pulmonary infections
US20150196589A1 (en) Formulations for alteration of biophysical properties of mucosal lining
US20080038207A1 (en) Method and device for decreasing contamination
US20050220720A1 (en) Formulations limiting spread of pulmonary infections
AU2006205108B2 (en) Method and device for decreasing contamination
AU2012202618A1 (en) Formulations for decreasing infectivity of pulmonary disease
AU2012258353A1 (en) Formulations for alteration of biophysical properties of mucosal lining
HK1167595A (en) Formulations for alteration of biophysical properties of mucosal lining
HK1156235A (en) Formulations for alteration of biophysical properties of mucosal lining
MX2007014468A (en) Formulations for alteration of biophysical properties of mucosal lining
HK1121064A (en) Formulations for alteration of biophysical properties of mucosal lining
HK1165990A (en) Formulations for alteration of biophysical properties of mucosal lining

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110613

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120307